Pure and viable human primary cells from peripheral blood, bone marrow and cord blood!  Disease state cells available now!


Choose from our large portfolio of cryopreserved cells isolated by expert scientists at HemaCare!


Quality Systems in place, from FDA-registered donor collection center to rigorous operational controls


Cell Tissues

Human hematopoietic stem cells and blood derived cell products are HemaCare’s specialty. We focus on peripheral blood, bone marrow, cord blood and mobilized peripheral blood so you can be assured you are getting the best blood products for your research.

See our tissues

Cell Types

HemaCare’s portfolio offers isolated hematopoietic cells from both the lymphoid production path and the myeloid lineage. Many are offered as either positive or negative selection using best in class immunomagnetic separation technology with our own proprietary protocols.

See our cell types

Disease State

If you need disease state whole blood, serum, plasma or mononuclear cells, HemaCare is your source!HemaCare’s portfolio includes infectious diseases, solid tumor and hematopoietic cancers, and autoimmune samples to further your research. If you can’t find what you are looking for, contact us!

See our disease states

Cell Therapy

Cell Therapy

From bench to bedside – we are committed to cell therapy and your success!

Apheresis collection is our specialty. With 40 years of experience, we have optimized cell collection by controlling and qualifying our apheresis procedure based on cGMP practices,  bringing a higher degree of reproducibility and quality product to research projects or manufacturing development.  Our extensive global portfolio of support services span non-clinical studies, clinical trials, and commercial product manufacturing, providing complementary resources and expertise to enhance your studies.

Our Laboratory:

See all accreditation and licensure here.

Our services and products include:

  • Apheresis leukopaks- fresh or cryo-preserved
  • Mobilized apheresis collections
  • Cell isolation (positive or negative selection)
  • PBMC
  • Customized donor selection
  • CofA includes count and viability
  • Serological testing

Learn more…

Our Latest News

Facility Relocation and Expansion Offers Fully-Integrated GMP Cell Therapy Services (Los Angeles, CA – September 4, 2018) HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announces details of their expanded GMP capabilities at the annual CAR-TCR Summit on September 4-7, […]

(Los Angeles – August 21, 2018) – HemaCare Corporation (OTC Pink: HEMA), a provider of human blood products and services in support of the rapidly expanding field of immune therapy, including stem cell therapy, today announced operational highlights and financial results for the six months ended June 30, 2018. First Half 2018 Operational Highlights Significant […]

Industry mavens strengthen HemaCare’s expertise in cell therapy and bioprocessing (Los Angeles, CA – July 17, 2018) HemaCare Corporation (OTCBB: HEMA), a global leader in the customization of human-derived biological products and services for biomedical research and cell therapy, today announced two new hires in senior leadership positions. Dr. Dominic Clarke joins the company as […]